
Twelve years of multiples investors have paid for Kopran Ltd, framed against the sector median so the premium or discount is obvious at a glance.
Kopran Ltd trades at a P/E of 38.72× and P/B of 1.28×.
Twelve years of audited numbers for Kopran Ltd, switchable between annual and quarterly views, consolidated or standalone.
Kopran Ltd reports its full P&L, balance sheet, cash flow and ratios on this page — current market capitalisation of ₹876.34 Cr and reported EPS of ₹3.41.
Disclosed business segments at Kopran with their share of revenue and profit, switchable between consolidated and standalone reporting.
Kopran discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.
Why someone would buy Kopran Ltd, why someone wouldn't, and the quantitative tripwires that would force the call to flip.
Kopran Ltd's investment case rests on 7 positive markers and 9 flagged concerns drawn from the latest reported filings.
Kopran Ltd exhibits a relatively low debt-to-equity ratio of 0.29, suggesting a manageable debt burden and a strong financial foundation for future growth and investment opportunities. This indicates a healthy balance sheet.
Despite recent quarterly profit variability, Kopran's promoter holding remains consistently high at approximately 44%, demonstrating significant confidence in the company's long-term prospects and potential for future value appreciation.
The company shows a positive return on equity (ROE) of 7.64%, indicating that Kopran Ltd is efficiently utilizing shareholder investments to generate profits. This is a key indicator of profitability and efficiency.
Kopran's operating profit margin (OPM) stands at a healthy 10.50%, suggesting efficient cost management and strong pricing power within its pharmaceutical industry. This demonstrates operational strength.
The pharmaceutical industry, where Kopran operates, is experiencing robust growth driven by increasing global healthcare expenditure and an aging population, presenting significant market expansion opportunities.
Kopran Ltd's quarterly profit has shown significant volatility, with a substantial -32.90% decrease in the most recent quarter. This needs further investigation to understand the underlying causes and potential future impact.
The recent stock price has experienced considerable fluctuation, falling from a 52-week high of ₹327 to a low of ₹154. This volatility presents a risk for investors seeking stability in their portfolios.
Kopran's relatively low Return on Capital Employed (ROCE) of 9.75% suggests that the company might not be utilizing its capital as efficiently as some of its competitors in the pharmaceutical sector. This warrants further analysis.
The company reported a quarterly sales decline of -3.03%, indicating potential challenges in revenue generation and market demand. This trend requires close monitoring for sustained performance.
The Price-to-Earnings (PE) ratio of 22.90, while not excessively high, warrants comparison to industry peers to accurately assess if it reflects the company's growth potential and future earnings.
Trim if P/E re-rates above 50. The valuation cushion thins from there.
Reassess if quarterly profit growth prints below 0% for two consecutive quarters. The bull case relies on compounding earnings.
Watch interest coverage if debt-to-equity climbs above 1.00. Balance sheet risk re-prices growth multiples fast.
Income thesis breaks if the dividend is cut or yield falls below 1.13%.
Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — Kopran Ltd is highlighted for quick read-across.
| Company Name |
|---|
Aarey Drugs & Pharmaceuticals Ltd |
Aarti Drugs Ltd |
Aarti Pharmalabs Ltd |
Ajanta Pharma Ltd |
Akums Drugs & Pharmaceuticals Ltd |
Albert David Ltd |
Alivus Life Sciences Ltd |
Alkem Laboratories Ltd |
Alpa Laboratories Ltd |
Amrutanjan Health Care Ltd |
Alembic Pharmaceuticals Ltd |
Astrazeneca Pharma India Ltd |
Aurobindo Pharma Ltd |
Bafna Pharmaceuticals Ltd |
Bajaj Healthcare Ltd |
Bal Pharma Ltd |
Biocon Ltd |
Biofil Chemicals & Pharmaceuticals Ltd |
Bliss GVS Pharma Ltd |
Blue Jet Healthcare Ltd |
Brooks Laboratories Ltd |
Caplin Point Laboratories Ltd |
Cipla Ltd |
Cohance Lifesciences Ltd |
Concord Biotech Ltd |
Dishman Carbogen Amcis Ltd |
Divis Laboratories Ltd |
Dr Reddys Laboratories Ltd |
Emcure Pharmaceuticals Ltd |
ERIS Lifesciences Ltd |
FDC Ltd |
Gland Pharma Ltd |
Glaxosmithkline Pharmaceuticals Ltd |
Glenmark Pharmaceuticals Ltd |
Granules India Ltd |
Gufic BioSciences Ltd |
Haleos Labs Limited |
Hester Biosciences Ltd |
Hikal Ltd |
Indoco Remedies Ltd |
Ind-Swift Laboratories Ltd |
Innova Captab Ltd |
IOL Chemicals & Pharmaceuticals Ltd |
Ipca Laboratories Ltd |
Jagsonpal Pharmaceuticals Ltd |
J B Chemicals & Pharmaceuticals Ltd |
Jubilant Pharmova Ltd |
Kilitch Drugs (India) Ltd |
Kopran LtdCurrent Stock |
Krebs Biochemicals & Industries Ltd |
Lasa Supergenerics Ltd |
Laurus Labs Ltd |
Lincoln Pharmaceuticals Ltd |
Lupin Ltd |
Lyka Labs Ltd |
Mangalam Drugs and Organics Ltd |
Mankind Pharma Ltd |
Marksans Pharma Ltd |
Medicamen Biotech Ltd |
Medico Remedies Ltd |
Morepen Laboratories Ltd |
Natco Pharma Ltd |
Nectar Lifescience Ltd |
Neuland Laboratories Ltd |
NGL Fine Chem Ltd |
OneSource Specialty Pharma Ltd |
Orchid Pharma Ltd |
Ortin Global Ltd |
Panacea Biotec Ltd |
Pfizer Ltd |
Procter & Gamble Health Ltd |
Piramal Pharma Ltd |
RPG Life Sciences Ltd |
Sai Life Sciences Ltd |
Sanofi India Ltd |
Sanofi Consumer Healthcare India Ltd |
Senores Pharmaceuticals Ltd |
Shilpa Medicare Ltd |
Sigachi Industries Ltd |
SMS Pharmaceuticals Ltd |
Solara Active Pharma Sciences Ltd |
Sun Pharma Advanced Research Company Ltd |
Strides Pharma Science Ltd |
Sun Pharmaceutical Industries Ltd |
Supriya Lifescience Ltd |
Syncom Formulations (India) Ltd |
Themis Medicare Ltd |
Torrent Pharmaceuticals Ltd |
Unichem Laboratories Ltd |
Valiant Laboratories Ltd |
Venus Remedies Ltd |
Vineet Laboratories Ltd |
Viyash Scientific Ltd |
Wanbury Ltd |
Windlas Biotech Ltd |
Wockhardt Ltd |
Zim Laboratories Ltd |
Zydus Lifesciences Ltd |
Live RSI, MACD and moving-average signals plus today's pivot and Central Pivot Range levels for Kopran Ltd — derived from the live tape, not yesterday's close.
Kopran Ltd last traded at ₹206.27 with an intraday range of ₹194.05–₹219 — live indicator, pivot and CPR signals below.
Standard pivot — most widely referenced.
| Level | Price (₹) | Distance | % Δ |
|---|---|---|---|
| R4 | 268.73 | +62.46 | +30.28% |
| R3 | 243.78 | +37.51 | +18.18% |
| R2 | 231.39 | +25.12 | +12.18% |
| R1 | 218.83 | +12.56 | +6.09% |
| PIVOT | 206.44 | 0.17 | 0.08% |
| CURRENT | 206.27 | — | — |
| S1 | 143.98 | -62.29 | -30.20% |
| S2 | 168.93 | -37.34 | -18.10% |
| S3 | 181.49 | -24.78 | -12.01% |
| S4 | 193.88 | -12.39 | -6.01% |
KOPRAN is trading Below CPR, indicating Bearishness
CPR is Narrower, suggesting likely for trending moves
Day's range: ~
Trading Above opening range, showing Bullishness
Daily traded volume and delivery percentage for Kopran Ltd over 20 sessions — the gap between intraday flipping and genuine accumulation.
Latest session delivery in Kopran Ltd stood at 27.3% of traded volume, against a 20-day average of 39.8%.
Filings Kopran sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.
Promoter, director and designated-employee transactions in Kopran as reported to SEBI — buying and selling signals from the people who know the business best.
Kopran insider activity below tracks 2 reported promoter, director and designated-employee transactions under SEBI Regulation 7(2).
| Insider | Category | Txn Date | Action | Quantity | Value (₹) | Price |
|---|---|---|---|---|---|---|
| Mridula Somani | Insider | 18 Dec 2024 | buy | +17.65 L | — | — |
| Mridula Somani | Insider | 18 Dec 2024 | buy | +17.65 L | — | — |
Every dividend, stock split and bonus issue Kopran has declared, sequenced by announce and record date.
Kopran corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.
What Kopran Ltd does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.
Kopran Ltd operates in the Pharmaceuticals industry under the Health Care sector, listed as NSE: KOPRAN, BSE: 524280.

Kopran Limited is an integrated pharmaceutical company with a long history, established in 1958 and headquartered in Mumbai, India. Its core business revolves around the manufacturing and marketing of both Active Pharmaceutical Ingredients (APIs) and finished dosage forms of pharmaceuticals. This encompasses a broad range of products distributed both domestically within India and internationally.
The company's product portfolio is extensive and diverse, covering numerous therapeutic categories. Their finished dosage forms include a variety of common pharmaceutical presentations such as tablets, capsules, syrups, dry powders, suspensions, and injectables. These forms are utilized to deliver medications across a wide spectrum of therapeutic areas.
Kopran offers both branded and generic formulations of drugs. The therapeutic areas covered by their products are substantial, including but not limited to: macrolides, antibacterials, anticonvulsants, anti-hypertensives, anti-helminthics, anti-acne medications, anti-infectives, anti-thrombotics, antidiabetics, pain management medications, neuromodulators, gastroenterology drugs, and cardiovascular medications. Furthermore, their offerings extend to drugs for erectile dysfunction, antiallergics, respiratory medications, oncology drugs, central nervous system medications, antiprotozoals, anthelmintics, antipeptic ulcer and gut medications, and various other therapeutic categories.
In summary, Kopran Limited operates as a fully integrated pharmaceutical company, encompassing API production and the manufacturing and marketing of a wide range of finished dosage forms across numerous therapeutic areas. Their long history and diverse product portfolio establish them as a significant player in the Indian and international pharmaceutical markets.
Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.
The current share price of Kopran Ltd (KOPRAN) is ₹206.27. Today, the stock has gained by ₹12.69 (6.56%), trading in a range of ₹194.05 to ₹219. The stock opened at ₹194.5 with a trading volume of 38,54,785 shares.
Kopran Ltd can be considered for long-term investment based on several factors. The company has a market capitalization of ₹876.34 crores, P/E ratio of 38.72, ROE of -0.05%, and ROCE of 9.75%. The dividend yield stands at 2.26%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
The 52-week high price of Kopran Ltd (KOPRAN) is ₹219, while the 52-week low is ₹107. Currently trading at ₹206.27, the stock is 88.6% away from its 52-week low and 5.8% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
Whether to buy Kopran Ltd stock at ₹206.27 depends on multiple factors. The stock is currently trading with a P/E ratio of 38.72 and P/B ratio of N/A. Today's performance shows a gain of 6.56%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
Kopran Ltd offers a dividend yield of 2.26%, which means for every ₹100 invested at the current price of ₹206.27, you can expect to receive approximately ₹2.26 annually as dividends. The face value of the stock is ₹10.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
Kopran Ltd's key financial metrics include: P/E Ratio: 38.72, P/B Ratio: N/A, ROE: -0.05%, ROCE: 9.75%, Dividend Yield: 2.26%, EPS: ₹3.41, Book Value: ₹107.35, Debt-to-Equity: 0.29, and Current Ratio: N/A. The company's market cap stands at ₹876.34 crores. These metrics help evaluate the company's valuation, profitability, and financial health.
Kopran Ltd stock opened at ₹194.5 and is currently trading at ₹206.27, showing a gain of ₹12.69 (6.56%). The intraday high is ₹219 and low is ₹194.05. The trading volume stands at 38,54,785 shares, indicating strong market participation today.
Kopran Ltd has a Price-to-Earnings (P/E) ratio of 38.72, which means investors are willing to pay ₹38.72 for every ₹1 of earnings. With an EPS of ₹3.41, this P/E ratio suggests the stock may be trading at a premium, possibly due to high growth expectations. Compare this with industry peers and historical P/E ratios for better context.
The data, ratios and commentary about Kopran Ltd (KOPRAN) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.
Peers, sector trends, screeners and strategy playbooks contextual to this stock.